Authors: Khaled K. Aldossari, Yazed AlRuthia, Ashraf Amir, Mohammed Alshurem, Hussein Elbadawi, Abdullah Kaki
Categories: Review, Abuse, Addiction, Education, Dependence, Gabapentinoid, Gabapentin, Misuse, Saudi Arabia, Pregabalin
Source: Pain and Therapy
Authors: Khaled K. Aldossari, Yazed AlRuthia, Ashraf Amir, Mohammed Alshurem, Hussein Elbadawi, Abdullah Kaki
Gabapentinoids, notably gabapentin and pregabalin, are crucial for managing neuropathic pain in conditions like diabetic neuropathy and specific types of cancer-related pain where opioids are ineffective or undesirable. However, the misuse potential of pregabalin has led to stricter regulatory controls in many regions, including Saudi Arabia. This expert opinion presents insights from multidisciplinary experts about the impact of these regulations on clinical practice, patient care, and misuse patterns in Saudi Arabia. Pregabalin’s rapid onset of action and probable euphoric effects make it more prone to misuse, especially among younger individuals and those with a history of substance abuse. Gabapentin, in contrast, has a lower abuse potential. Experts discussed the implementation of the National Platform for Narcotic Drugs and Psychotropic Substances (Raqeeb) in Saudi Arabia, a system designed to monitor prescriptions of controlled substances. While effective in curbing over-prescription, it has also introduced unintended challenges. Physicians, fearing scrutiny, often hesitate to prescribe gabapentinoids, leading to delays in treatment and greater reliance on less appropriate alternatives. Moreover, stigma associated with controlled substances has further discouraged patients from seeking treatment, resulting in undertreated pain and a diminished quality of life. This expert opinion highlights the need for a more balanced approach to gabapentinoid regulation. It advocates for improved physician education on the management of neuropathic pain, and public awareness initiatives to curb misuse, reduce stigma, and promote the safe use of medications. Refining the Raqeeb platform could alleviate administrative burdens while ensuring robust oversight. Finally, adopting a risk-stratified approach to prescription would allow close monitoring of high-risk patients for substance abuse while ensuring that low-risk patients maintain access to essential treatments. Addressing these challenges would enable healthcare authorities to prevent abuse while ensuring effective pain relief for patients with legitimate medical needs.
Gabapentinoids, especially gabapentin and pregabalin, are widely used for the management of neuropathic pain in Saudi Arabia. However, concerns about their potential for misuse, particularly with pregabalin, have led to stricter regulatory scrutiny.This paper highlights the implications of regulatory changes, focusing on both the abuse potential and its impact on clinical practice in Saudi Arabia.Pregabalin abuse is often associated with personality disorders and concurrent substance use, while gabapentin exhibits a lower propensity for abuse.Due to these concerns, Saudi Arabia has implemented the Raqeeb platform to monitor prescriptions of controlled substances, including gabapentinoids. Expert recommendations suggest that regulatory measures should differentiate between these medications to ensure appropriate patient access while effectively mitigating the risk of abuse.
Gabapentinoids, including gabapentin and pregabalin, are widely prescribed for managing neuropathic pain by inhibiting calcium-mediated neurotransmitter release through their effects on a2d-1 subunits [1, 2]. This mechanism, along with their more favorable safety profile than opioids, has made them invaluable in treating conditions like diabetic neuropathy, fibromyalgia, and postherpetic neuralgia [1, 3]. However, concerns about their misuse and abuse have led to heightened regulatory scrutiny worldwide, including in Saudi Arabia [4–12]. A global study reported a 17.2% annual increase in gabapentinoid consumption between 2008 and 2018, with high-income countries averaging 39.9 defined daily doses per ten thousand inhabitants per day (DDD/TID) in 2018, compared with 6.1 DDD/TID in low- and middle-income countries. Despite differences in healthcare systems, the escalating use of gabapentinoids reflects a growing reliance on these agents and underscores the associated risks of abuse [13]. Other studies also emphasize the notable rise in global gabapentinoid use [14, 15].
In response to these concerns, Saudi Arabia reclassified gabapentinoids as controlled substances in the year 2017 [16]. This decision, primarily driven by concerns over abuse, particularly involving pregabalin, placed these medications under stricter regulatory oversight [16–18]. Subsequent studies showed a significant decline in pregabalin prescriptions, coupled with an increase in gabapentin utilization [17].
To support this reclassification, the Saudi Food and Drug Authority (SFDA) and, Saudi Ministry of Health implemented the Raqeeb platform [19, 20]. This national monitoring system tracks prescriptions of narcotics and psychotropic substances, including gabapentinoids. It enables healthcare practitioners to review a patient’s medication history, enhancing prescribing safety and preventing over-prescription. Moreover, it governs pharmacy dispensing but does not regulate illicit distribution through the black market. While this initiative has played a key role in curbing over-prescription and potential abuse, it has also introduced challenges to clinical practice. Physicians face challenges in balancing regulatory compliance with effective patient care. Additionally, data on the broader impact of these regulatory changes on prescribing practices and pain management remain limited.
This review article offers expert opinions on the complex challenges posed by gabapentinoid regulation in Saudi Arabia. It provides an in-depth analysis of how regulatory changes have shaped clinical practices and highlights potential strategies to optimize pain management while mitigating the risks of gabapentinoid abuse and misuse. By addressing these concerns, this paper aims to strike a balance between ensuring public safety and meeting the critical need for effective pain relief in patients who depend on these medications for their quality of life (QoL).
An advisory board meeting was conducted on May 3, 2024, in Saudi Arabia, bringing together a diverse group of experts, including a family physician, psychiatrist, anesthesiologist and pain physician, clinical pharmacist, neurologists, and a pharmacoeconomist. The primary aim of the meeting was to identify and address the challenges associated with prescribing gabapentinoids and managing pain, particularly in the context of regulatory changes affecting their use.
Experts who participated in this advisory board meeting were selected based on their clinical experience, and contributions to pain management research or practice within Saudi Arabia. The selection ensured representation across disciplines and healthcare sectors (public and private). All participating experts provided disclosures regarding any potential conflicts of interest prior to the meeting; and any such conflicts have been duly declared by the authors. This review article is based on previously conducted studies and does not involve any new research with human participants or animals by the authors. Therefore, ethical approval was not required.
To ensure a comprehensive discussion, a detailed literature review was conducted prior to the meeting. The review covered published evidence retrieved from PubMed, Google Scholar, and the Cochrane Library, without any date restrictions. The evidence gathered provided a foundation for discussions on current prescribing practices and trends related to gabapentinoid use in Saudi Arabia. The meeting focused on challenges arising from the reclassification of gabapentinoids as controlled substances, as per SFDA circular no. 551635, December 10, 2017, and the impact of the implementation of Raqeeb platform, which monitors prescription practices, as outlined in SFDA directive no. 3822-1443, March 14, 2022. Key objectives included ensuring effective pain management for patients in need, minimizing the potential for abuse, and identifying practical solutions to enhance clinical practices.
During the meeting, the discussions were moderated and documented in real time. The resulting summary was thematically organized by the authors and shared with all panelists for review. Feedback was incorporated through iterative email communication to ensure accuracy and collective agreement. The discussions were refined and structured into key thematic areas, drawing extensively on the latest studies and the clinical expertise of the panel. These themes focused on strategies to optimize the safe and effective use of gabapentinoids while addressing the critical need to reduce the risk of abuse. This process ensured that the recommendations were firmly rooted in evidence-based practices while reflecting the collective expertise of the multidisciplinary panel. Consequently, a comprehensive framework was developed to navigate the regulatory and clinical challenges associated with the use of gabapentinoids in Saudi Arabia.
Publication writing assistance for the development of this manuscript was provided by Tata Consultancy Services. The medical writers received the summary of the advisory meeting along with additional notes, and they were informed about the manuscript's objectives. Throughout the drafting process, the manuscript was created with the guidance of experts, whose feedback was integrated at every stage. This has been disclosed here to ensure transparency, given the nature of this expert opinion article.
The expert meeting was recorded and transcribed, topics were organized in themes and the panel’s main points and recommendations were summarized.
The regulation, prescribing, and oversight of gabapentinoids, including gabapentin and pregabalin, has become increasingly complex due to concerns over abuse and the need for optimized pain management. Gabapentinoids are pivotal in managing neuropathic pain and are widely recognized as first-line therapies. They are frequently used as opioid-sparing alternatives in palliative care, particularly for patients experiencing specific types of terminal cancer pain, such as those with neuropathic components. Despite their therapeutic importance, regulatory restrictions have introduced significant challenges to clinical practice. These medications remain essential for treating conditions, such as diabetic peripheral neuropathy, postherpetic neuralgia, and chronic back pain with neuropathic components, such as radicular pain. Achieving a balance between regulatory control and optimizing clinical application is essential; this involves safe, effective, and evidence-based prescribing of gabapentinoids, tailored to meet the specific needs and risk profiles of individual patients. Moreover, it is critical to assess the impact of regulatory policies to ensure that they do not compromise patient access or treatment efficacy.
Before the SFDA’s restrictions on pregabalin, gabapentin addiction was rarely reported. A notable preference for pregabalin over gabapentin in cases of abuse has been consistently documented. Due to its rapid onset and euphoric effects, pregabalin carries a higher risk of misuse than gabapentin, particularly among younger individuals. This distinction is supported by data from a representative sample of the French population, where notably higher rate of misuse was observed in pregabalin compared to gabapentin users (12.8% vs. 6.6%; p < 0.001) [21]. Additionally, a higher proportion of pregabalin users experienced a first episode of misuse compared to gabapentin users (11.3% vs. 5.9%). Moreover, personality disorders were frequently associated with pregabalin misuse, which was not observed in gabapentin users [21].
Moreover, the prevalence of lifetime abuse is reported to be consistently lower with gabapentin [22]. Gabapentin received its first market authorization in the USA in 1993, nearly 17 years before the European Medicines Agency issued a warning regarding its potential for abuse [23, 24]. During this period, there were no significant issues of abuse linked to gabapentin. In contrast to pregabalin, the Saudi summary of product characteristics does not list euphoria as an adverse event associated with gabapentin [25, 26]. Furthermore, in the USA, there is no federal-level control of gabapentin utilization by the Drug Enforcement Administration [27]. However, since 2016, more than 26 states have reclassified gabapentin as a Schedule V medication at the state level or introduced mandatory reporting to prescription drug monitoring programs, such as the Ohio Automated Rx Reporting System [28–30]. Similarly, the risk of misuse, abuse, or dependence with gabapentin is not mentioned in the French SmPC, highlighting its lower misuse potential relative to pregabalin [21]. However, it should be noted that in October 2022, the EMA’s CMDh mandated the inclusion of specific warnings regarding the abuse potential of gabapentin in all EU Summary Product Characteristics (SmPC) [31]. Moreover, SmPCs often lag scientific developments and may not always reflect the most current understanding of the safety profile of medications.
Gabapentinoids are integral to the standard care of a wide range of neuropathic conditions. These include peripheral neuropathies such as diabetic polyneuropathy, central conditions like fibromyalgia, and mixed pain types such as specific types of cancer-related pain with neuropathic components. They are particularly valuable when opioids are ineffective or undesirable. When used in combination with opioids, gabapentinoids contribute to a decrease in the overall opioid doses needed, which minimizes the risks associated with opioid therapy, such as the development of tolerance and potential for addiction. However, this opioid-sparing effect has also led to gabapentin being misused as an “opioid-enhancer” by those struggling with opioid addiction, which varies across patients. Those at a higher risk of pregabalin abuse often have a history of substance abuse, particularly with benzodiazepines and marijuana [32]. Age also influences misuse patterns. Younger individuals are more likely to misuse pregabalin, while elderly patients are less prone due to intolerance to its side effects [21, 33]. Therefore, restricting gabapentinoid use among the elderly population may not be necessary, given their lower risk of developing addiction. Addressing these differences is essential in shaping regulations and clinical practices that minimize misuse while ensuring continued access to these vital medications for patients who genuinely benefit from them.
A significant factor contributing to the inappropriate use of gabapentin is the lack of emphasis on pain management in medical education. As per a systematic literature review on pain medicine education in 383 medical schools in Australia, New Zealand, USA, Canada, UK, and Europe, the median number of hours dedicated to pain medicine in the entire curriculum ranged between 11 and 20 h [34]. Furthermore, it was noted that pain medicine is mainly taught within anesthesia or pharmacology courses, rather than as a separate module. In the UK and USA, 96% of medical schools and about 80% in Europe do not have compulsory pain medicine education [34]. Several studies from Saudi Arabia have also highlighted the lack of adequate training in pain management for both medicine and nursing students, suggesting the need for improved educational programs and formal curriculum on pain medicine [35–38]. Medical students, on average, receive only 13 h of pain management training (ranging from 6 to 50 h) compared to their veterinary counterparts, who receive around 27.4 h (ranging from 8.8 to 43 h) [39]. This inadequacy in training highlights a critical gap in the preparedness of physicians to manage pain effectively and differentiate the types of pain, which may lead to poor prescribing practices and improper titration of medications like gabapentin and pregabalin, thus increasing the risk of misuse and side effects. For example, there may be instances of prescribing higher doses when lower-dose options, such as gabapentin 100 mg are not available. In addition, the lack of targeted, evidence-based training contributes to both under-treatment and inappropriate prescribing patterns. Many healthcare providers, especially general practitioners and non-specialists, may not feel adequately equipped to assess neuropathic pain or balance the risk–benefit profile of gabapentinoids. This contributes to variability in clinical decisions, hesitancy in prescribing even when clinically indicated, and potential over-reliance on less appropriate alternatives. Enhancing pain education is essential not only to improve patient outcomes but also to assist prescribers in navigating regulatory frameworks and reducing misuse risks. Therefore, it is imperative to improve education and training in pain management to ensure the effective use of gabapentinoids in clinical practice.
The trending focus that was aligned with the introduction of the Raqeeb platform in Saudi Arabia has raised concerns among healthcare providers. While its goal is to monitor and prevent over-prescription of controlled substances, physicians often face the risk of being flagged for prescribing gabapentinoids. This has resulted in increased caution and hesitancy, even when these medications are clinically indicated. In some cases, physicians have opted to prescribe alternative medications like duloxetine, amitriptyline, carbamazepine, or sometimes tramadol to avoid potential scrutiny, particularly for patients who are stable and receiving treatment with gabapentinoids. A cross-sectional study from Saudi Arabia found that after the implementation of a restricted pregabalin prescription policy, there was a significant reduction in pregabalin use, which was accompanied by an increased use of opioids such as tramadol and acetaminophen/codeine [40]. This shift towards alternative pain management options may not be as effective for certain patients and may carry their own risks, for instance, the risk of falls in elderly patients, which is 48% less with gabapentin than duloxetine [41, 42]. Further, the hesitancy among the prescribers not only delays the treatment of patients with chronic pain but also disrupts the continuity of care for those who have long relied on gabapentinoids for pain management. These regulatory challenges place an additional administrative burden on physicians, potentially leading to suboptimal pain management strategies.
The reclassification of gabapentinoids as controlled substances in Saudi Arabia has considerably impacted patients who rely on these medications for managing chronic pain. Many individuals, particularly those on long-term gabapentinoid therapy, are now reluctant to continue treatment due to concerns about being perceived as drug abusers. This stigma associated with controlled substances can lead to patients discontinuing treatment or avoiding necessary adjustments, resulting in inadequate pain management and a deterioration in QoL. The stigma is exacerbated by public perceptions that these drugs are mainly associated with addiction, overshadowing the legitimate medical needs.
Furthermore, the unavailability of lower-dose formulations, such as gabapentin 100 mg, exacerbates the problem. This specific dose is often unavailable in the Saudi market or in hospital formularies, forcing physicians to initiate therapy at higher doses. In response, some prescribers suggest a workable solution, advising patients to open a gabapentin 300-mg capsule, dissolve the contents in a liquid, consume half, and discard the rest. Although this approach helps reduce excessive initial higher doses and facilitates more gradual titration, it is not an ideal or sustainable long-term approach. This lack of lower-dose options remains a critical concern, emphasizing the need for better access to appropriate formulations to ensure safe, effective, and tailored pain management.
Pain is inherently subjective, which complicates efforts to assess the abuse potential. Patients with substance use disorder may exhibit drug-seeking behavior, making it difficult for prescribers to distinguish between legitimate medical needs and abuse. In Jeddah, multiple autopsy reports have not directly implicated pregabalin abuse as a cause of death. However, pregabalin has been identified in conjunction with other toxic substances such as heroin and methamphetamine, highlighting its abuse in these instances [43]. Tough measures restricting access to gabapentinoids may push individuals at risk towards alternative sources.
Addressing substance use disorders requires a holistic approach, targeting both the symptoms of dependance and the underlying causes, such as mental health issues, previous instances of substance abuse, and social factors. A comprehensive policy review is necessary to ensure that restrictions on gabapentinoids alone are not enacted to solve the problem but also address the underlying behavioral aspects. This approach will help prevent unintended consequences, such as a rise in the use of more harmful substances or restricted access to legitimate patients with neuropathic pain to effective treatments.
To address the challenges posed by the reclassification of gabapentinoids, it is crucial to implement comprehensive updated prescribing guidelines. The variations in the risk of abuse among specific patient populations, such as the elderly or those with epilepsy or terminal illnesses, need to be addressed to ensure that these patients continue to receive the necessary treatment without facing barriers to pain management. Additionally, these guidelines should offer detailed guidance for specific cases, such as transitioning patients from gabapentin and pregabalin, or from opioids to gabapentinoids, which could enhance patient care while minimizing misuse and medication errors. Restrictions should be tailored to the specific characteristics of each molecule, ensuring gabapentin is managed according to its lower risk for abuse and broader therapeutic dose range. Precautionary measures should focus on patients receiving high doses or those at higher risk of misuse, balancing safety with therapeutic efficacy.
While the Raqeeb platform is essential for monitoring controlled substances, its current implementation imposes a significant administrative burden on healthcare providers. Physicians report that navigating the system is time-consuming, which hinders their focus on patient care. Optimizing the platform’s functionality will aid in streamlining workflows, reducing administrative strain, and encouraging increased compliance with regulatory requirements. To improve efficiency and usability, the platform should integrate simplified data entry, automated prescription tracking, and clearer reporting mechanisms. Also, integrating a diagnosis verification tool for high-risk patients would support clinical decision making, ensuring that prescriptions are appropriate, justified, and aligned with best practices while minimizing the risk of misuse.
Implementing risk stratification tools can effectively identify patients at higher risk of misusing/abusing gabapentinoids. Key risk factors include a history of substance abuse, mental health disorders, chronic illness, familial instability, a feeling of loneliness and disconnection, and living in unhealthy environments. This approach aligns seamlessly with Saudi Arabia’s Vision 2030, which emphasizes protecting families as the cornerstone of a stable society across generations. Furthermore, men are generally at a higher risk of substance misuse/abuse compared to women, which is influenced by a range of cultural and environmental factors.
By employing tools like the DN4 questionnaire, physicians can ensure accurate diagnosis and create tailored treatment plans [44]. High-risk patients, including those with the aforementioned risk factors, should be monitored more closely, such as tracking for high dose prescriptions, dispensing for less duration, or asking for diagnosis reassurance. In contrast, low-risk patients, such as the elderly, should not face unnecessary barriers to access pain management therapies. This approach ensures that prescribing practices are tailored to individual needs, allowing safe and appropriate access to gabapentinoids for those who need them while maintaining vigilant oversight on those at higher risk.
Introducing patient questionnaires and obtaining consent for potential random drug testing (urine or blood samples for high-risk users) could help physicians assess a patient’s risk for misuse/abuse during treatment. This measure would not only help identify potential risks early but also support the ongoing need for monitoring throughout the course of treatment. It could alleviate concerns about misuse/abuse while maintaining access to gabapentinoids for patients with legitimate needs, ensuring that both patient safety and appropriate access to treatment are prioritized.
Ensuring the availability of low-dose gabapentinoid formulations, such as gabapentin 100 mg, is crucial for safe and individualized treatment initiation. Restoring access to these lower doses would help minimize unnecessary side effects and reduce the risk of dependence, allowing for more precise dose adjustments in clinical practice.
A significant factor contributing to gabapentinoid misuse is the lack of comprehensive education among physicians regarding appropriate dosing and pain management strategies. Many physicians, particularly those outside of specialized pain clinics, are not well-versed in the nuances of gabapentinoid pharmacology. As a result, inappropriate prescribing, such as inaccurate diagnosis, abrupt discontinuation or sudden withdrawal of high doses without proper titration can increase the risk of abuse and dependence. Addressing this educational gap through targeted training programs focused on pain management and appropriate dosing strategies can significantly improve prescribing practice, reduce the risk of misuse, and enhance patient outcomes.
Patient education initiatives are essential for reducing stigma surrounding gabapentinoids and enhancing patient understanding of their proper use. These campaigns should emphasize that, when used correctly, gabapentinoids can significantly improve QoL, while also educating patients on the risks of abuse. Importantly, patients must understand the differences between gabapentin and pregabalin, particularly regarding dosing and potency, as many are unaware of the distinctions. Contrary to common assumptions about substance addiction, gabapentinoid abuse is often associated with individuals who have higher levels of education and greater knowledge. These individuals may also have better access to pharmaceutical alternatives than street drugs, necessitating a more targeted approach to public education.
Campaigns should also emphasize the importance of gradual tapering to prevent withdrawal symptoms and reduce the likelihood of patients self-medicating or adjusting their dosage without medical supervision. Proper education on dose titration and the risk of abrupt discontinuation is critical for both preventing misuse and ensuring effective, long-term pain management.
Implementing a system for defining high-risk patients would enable physicians to prescribe with confidence, knowing that these individuals are being closely monitored. This could also reduce the regulatory pressure on low-risk patients and allow for more effective pain management.
It is vital to conduct studies focused on gabapentinoids abuse in Saudi Arabia to get a deeper understanding of the associated risk factors, which will facilitate the development of more targeted interventions. More research in this area would enhance our knowledge of misuse/abuse patterns and inform future policy frameworks.
Physicians need well-defined protocols to manage suspected cases of gabapentinoid abuse. Standardized guidelines for tapering therapy or transitioning patients to alternative treatments must be standardized to ensure consistent, safe, and effective care.
The reclassification of gabapentinoids in Saudi Arabia has introduced tangible challenges for both healthcare providers and patients. Gabapentinoids, such as pregabalin and gabapentin, are essential for managing neuropathic pain, particularly in conditions like diabetic neuropathy and specific types of cancer-related pain. However, pregabalin’s higher abuse potential has led to stricter regulations, which have directly impacted prescribing practices and patient access.
The Raqeeb platform has been effective in tracking prescriptions and reducing the risk of misuse. However, it has also increased physician hesitancy to prescribe gabapentinoids, even when clinically appropriate. This reluctance has led to a suboptimal reliance on alternative medications, such as duloxetine, amitriptyline, and carbamazepine, which may not be as effective for certain patients. Additionally, the heightened stigma surrounding these medications has caused many patients to associate gabapentinoids with addiction, leading to untreated pain and diminished QoL. A patient-centered perspective highlights this issue further. For instance, a 62-year-old patient with type 2 diabetes mellitus and peripheral neuropathy had previously experienced substantial pain relief with pregabalin. However, following its reclassification, the physician, concerned about regulatory scrutiny, chose to prescribe alternative treatments that failed to provide similar relief. The patient, who was also undergoing treatment for hypertension and hepatic impairment, became hesitant to pursue further pharmacological options due to the perceived stigma. Consequently, the patient experienced worsening pain, poor sleep, reduced mobility, and a significant decline in QoL. Such real-world cases reflect the unintended consequences of restrictive policies and emphasize the need for a unique approach that safeguards access while ensuring appropriate use.
A tailored, risk-based approach is essential for addressing these challenges. High-risk patients should be monitored closely, while low-risk groups, such as elderly or terminally ill patients, should retain uninterrupted access to necessary treatments. Optimizing the Raqeeb platform and enhancing physician education can help alleviate regulatory burdens and improve prescribing practices. Additionally, public education campaigns are crucial to reduce stigma and promote informed medication use, which in turn will empower patients to feel more comfortable in seeking treatment and adhering to prescribed therapies.
By adopting these strategies, Saudi Arabia can ensure effective pain management while minimizing the risk of misuse, striking a balance between patient care and regulatory oversight. Table 1 provides a structured overview of key areas for improving the regulation and management of gabapentinoids, ensuring safety while maintaining access for patients in need.Table 1Recommendations for optimizing gabapentinoid managementCategoryRecommendationsPhysician educationEnhance physician training on accurate pain diagnosis and safe prescribing practices, and gabapentinoid pharmacologyProvide targeted pain management programs, especially for non-specialistsPublic educationLaunch public campaigns to reduce stigma and educate on the safe use of gabapentinoidsEmphasize the importance of following prescribed doses and avoiding abrupt discontinuationRegulatory adjustmentsOptimize and simplify the Raqeeb platform to streamline monitoring and reduce the administrative burden on healthcare providersDevelop more flexible prescribing guidelines to allow exemptions for low-risk populations, such as elderly, epilepsy or terminally ill patientsAssure no-punitive actions for prescribing gabapentinoids per se so long as the diagnosis is accurate, and risk measures are taken based on patient stratificationRisk-based prescribingImplement risk stratification tools to access individual abuse risk based on factors like age, history of substance abuse, and mental health disordersClosely monitor high-risk patients, while easing restrictions for low-risk groupsRevamp the restriction based on the specific molecule characteristics so that gabapentin is dealt with based on its lower risk for abuse and wider therapeutic dose rangeExcise caution with high doses in high-risk patients to minimize risksAccess to lower dosesIncrease the availability of lower-dose gabapentinoid formulations (e.g., gabapentin 100 mg) to reduce the risk of misuse and side effectsProvide guidance on titration and gradual taperingAlternative therapiesEnsure that gabapentinoids are not unnecessarily replaced by less effective or riskier drugs like tramadol or other strong opioidsPatient consent and monitoringIntroduce patient questionnaires and consent for potential drug testing (urine or blood samples) before prescribingImplement a system for tracking high-risk patients to ensure appropriate oversightResearch and policy developmentConduct studies on the risk factors and common traits of abusers to facilitate an informed stratification of gabapentinoid usersDevelop a protocol for prescribing gabapentinoids based on patient classification
The reclassification of gabapentinoids in Saudi Arabia represents a necessary regulatory step in addressing the rising concern of misuse. However, these regulatory changes have also introduced significant challenges for both healthcare providers and patients. Physician hesitancy to prescribe gabapentinoids, combined with patient stigma, has led to under-treatment of pain and a shift toward less effective alternatives.
To overcome these challenges, a multifaceted approach is required. Enhancing physician education on appropriate prescribing practices is essential to ensure that these medications are used safely and effectively. Additionally, optimizing the Raqeeb platform to reduce administrative burdens can help physicians navigate the regulatory framework without compromising patient care. Public education campaigns are equally important, as they can address the stigma surrounding gabapentinoids and correct the common misconceptions about their use.
A risk-based patient stratification approach that considers individual factors such as age, substance use history, and medical needs can help ensure that prescribing decisions are tailored to patient risk profiles. By refining regulatory and clinical practices, it is possible to strike a balance between preventing abuse and ensuring access to effective pain management solutions (Fig. 1).Fig. 1Comprehensive overview of gabapentinoid impacts, solutions, and outcomes
We believe that recognizing the various risk profiles and medical needs of different patient groups, such as elderly individuals, patients with epilepsy, and those with terminal illness, is crucial. Instead of imposing uniform restrictions, a tailored approach would provide better support for patients with neuropathic pain who are disproportionately affected by blanket policies. By implementing evidence-based, patient-centered solutions, Saudi Arabia can preserve access to essential treatments while safeguarding against abuse.